BR112021006229A2 - composto, composição farmacêutica, e, método para tratamento de um câncer - Google Patents
composto, composição farmacêutica, e, método para tratamento de um câncerInfo
- Publication number
- BR112021006229A2 BR112021006229A2 BR112021006229A BR112021006229A BR112021006229A2 BR 112021006229 A2 BR112021006229 A2 BR 112021006229A2 BR 112021006229 A BR112021006229 A BR 112021006229A BR 112021006229 A BR112021006229 A BR 112021006229A BR 112021006229 A2 BR112021006229 A2 BR 112021006229A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- treating
- compound
- pharmaceutical composition
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Testing Relating To Insulation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
a invenção refere-se a compostos da fórmula (i), em que r1, r2, r3, r4, r5 e são conforme definido na descrição.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306294.2A EP3632908A1 (en) | 2018-10-02 | 2018-10-02 | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
| PCT/EP2019/076681 WO2020070181A1 (en) | 2018-10-02 | 2019-10-02 | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021006229A2 true BR112021006229A2 (pt) | 2021-07-06 |
Family
ID=63857833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021006229A BR112021006229A2 (pt) | 2018-10-02 | 2019-10-02 | composto, composição farmacêutica, e, método para tratamento de um câncer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11999758B2 (pt) |
| EP (2) | EP3632908A1 (pt) |
| JP (1) | JP7430715B2 (pt) |
| KR (1) | KR20210072001A (pt) |
| CN (1) | CN113039182B (pt) |
| AU (1) | AU2019352009B2 (pt) |
| BR (1) | BR112021006229A2 (pt) |
| CA (1) | CA3114375A1 (pt) |
| DK (1) | DK3860990T3 (pt) |
| ES (1) | ES2931150T3 (pt) |
| HU (1) | HUE059965T2 (pt) |
| IL (1) | IL281999B2 (pt) |
| MX (1) | MX2021003843A (pt) |
| PL (1) | PL3860990T3 (pt) |
| PT (1) | PT3860990T (pt) |
| SI (1) | SI3860990T1 (pt) |
| WO (1) | WO2020070181A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| CA3194456A1 (en) | 2020-09-30 | 2022-04-07 | Arnaud Marchand | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer |
| AR125350A1 (es) | 2021-04-16 | 2023-07-12 | Orion Corp | Inhibidores tead |
| WO2023042901A1 (ja) * | 2021-09-16 | 2023-03-23 | 慶應義塾 | 小細胞肺癌患者ｃｔｃ由来オルガノイド製造と小細胞肺癌分子標的治療薬としてのｉｇｆ１ｒ阻害剤 |
| CN116239498B (zh) * | 2023-05-11 | 2023-07-21 | 北京元延医药科技股份有限公司 | 制备克立硼罗中间体的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5306818A (en) | 1990-11-01 | 1994-04-26 | Sterling Winthrop Inc. | Tetrahydro 2-saccharinylmerthyl aryl carboxylates |
| US6200957B1 (en) | 1995-12-14 | 2001-03-13 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6011034A (en) | 1998-02-12 | 2000-01-04 | Uniroyal Chemical Company, Inc. | Insecticidal dihydrooxadiazine compounds |
| CA2494421A1 (en) | 2002-08-06 | 2004-02-12 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
| ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
| CN101312968A (zh) | 2005-09-23 | 2008-11-26 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途 |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| US20100160424A1 (en) | 2007-06-20 | 2010-06-24 | Baldwin John J | Renin inhibitors |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| EP3109249A1 (en) | 2007-11-15 | 2016-12-28 | YM BioSciences Australia Pty Ltd | N-containing heterocyclic compounds |
| JP5578490B2 (ja) * | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| FR2942797B1 (fr) | 2009-03-03 | 2011-04-29 | Pf Medicament | Derives de benzothiazines, leur preparation et leur application a titre de medicaments |
| EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| US9040524B2 (en) | 2010-12-21 | 2015-05-26 | Janssen Pharmaceutica Nv | Antifungal 5,6-dihydro-4H-pyrrolo[1,2-a][1,4]-benzodiazepines and 6H-pyrrolo[1,2-a][1,4]benzodiazepines substituted with bicycle benzene derivatives |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| AU2012340869B2 (en) | 2011-11-23 | 2017-03-02 | Cancer Research Technology Limited | Thienopyrimidine inhibitors of atypical protein kinase C |
| WO2013123071A1 (en) | 2012-02-13 | 2013-08-22 | Cleave Biosciences, Inc. | Methods and compositions for jamm protease inhibition |
| ES2689541T3 (es) | 2012-06-19 | 2018-11-14 | Rutgers, The State University Of New Jersey | Agentes antibacterianos: derivados de aril mixopironina |
| US9737522B2 (en) | 2012-08-09 | 2017-08-22 | Emory University | NMDA receptor modulators and uses related thereto |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| US9458124B2 (en) | 2013-02-06 | 2016-10-04 | Wayne State University | Substituted pyran derivatives |
| US20160096850A9 (en) | 2013-08-22 | 2016-04-07 | Genentech, Inc. | Alkynyl alcohols and methods of use |
| EP3086644A1 (en) * | 2013-12-23 | 2016-11-02 | Syngenta Participations AG | Benzoxaborole fungicides |
| CN106852142B (zh) | 2014-10-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 作为醛固酮合酶抑制剂的螺二胺衍生物 |
| ES2883938T3 (es) | 2014-12-29 | 2021-12-09 | Us Health | Inhibidores de molécula pequeña de lactato deshidrogenasa y métodos de utilización de los mismos |
| JP6887996B2 (ja) * | 2015-09-23 | 2021-06-16 | ザ ジェネラル ホスピタル コーポレイション | Ｔｅａｄ転写因子自己パルミトイル化阻害剤 |
| EP3156404A1 (en) * | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| WO2017133517A1 (zh) | 2016-02-03 | 2017-08-10 | 四川海思科制药有限公司 | 一种磷酰胺衍生物及制备方法和用途 |
| CN109912609A (zh) * | 2017-12-12 | 2019-06-21 | 江苏三月光电科技有限公司 | 一种以含氮五元杂环为母核的化合物及其在有机电致发光器件上的应用 |
-
2018
- 2018-10-02 EP EP18306294.2A patent/EP3632908A1/en not_active Withdrawn
-
2019
- 2019-10-02 BR BR112021006229A patent/BR112021006229A2/pt unknown
- 2019-10-02 CA CA3114375A patent/CA3114375A1/en active Pending
- 2019-10-02 DK DK19782584.7T patent/DK3860990T3/da active
- 2019-10-02 KR KR1020217011255A patent/KR20210072001A/ko active IP Right Grant
- 2019-10-02 MX MX2021003843A patent/MX2021003843A/es unknown
- 2019-10-02 US US17/278,429 patent/US11999758B2/en active Active
- 2019-10-02 HU HUE19782584A patent/HUE059965T2/hu unknown
- 2019-10-02 ES ES19782584T patent/ES2931150T3/es active Active
- 2019-10-02 EP EP19782584.7A patent/EP3860990B1/en active Active
- 2019-10-02 WO PCT/EP2019/076681 patent/WO2020070181A1/en active Application Filing
- 2019-10-02 PT PT197825847T patent/PT3860990T/pt unknown
- 2019-10-02 AU AU2019352009A patent/AU2019352009B2/en active Active
- 2019-10-02 IL IL281999A patent/IL281999B2/en unknown
- 2019-10-02 CN CN201980075645.2A patent/CN113039182B/zh active Active
- 2019-10-02 JP JP2021518089A patent/JP7430715B2/ja active Active
- 2019-10-02 PL PL19782584.7T patent/PL3860990T3/pl unknown
- 2019-10-02 SI SI201930344T patent/SI3860990T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210072001A (ko) | 2021-06-16 |
| EP3632908A1 (en) | 2020-04-08 |
| ES2931150T3 (es) | 2022-12-27 |
| JP7430715B2 (ja) | 2024-02-13 |
| US11999758B2 (en) | 2024-06-04 |
| AU2019352009A1 (en) | 2021-04-15 |
| PT3860990T (pt) | 2022-10-18 |
| IL281999B2 (en) | 2024-03-01 |
| CN113039182B (zh) | 2024-02-20 |
| DK3860990T3 (da) | 2022-12-19 |
| JP2022504077A (ja) | 2022-01-13 |
| MX2021003843A (es) | 2021-05-27 |
| IL281999A (en) | 2021-05-31 |
| US20210323982A1 (en) | 2021-10-21 |
| AU2019352009B2 (en) | 2024-04-04 |
| CA3114375A1 (en) | 2020-04-09 |
| HUE059965T2 (hu) | 2023-01-28 |
| PL3860990T3 (pl) | 2023-01-23 |
| WO2020070181A1 (en) | 2020-04-09 |
| CN113039182A (zh) | 2021-06-25 |
| EP3860990B1 (en) | 2022-09-14 |
| IL281999B1 (en) | 2023-11-01 |
| SI3860990T1 (sl) | 2022-11-30 |
| EP3860990A1 (en) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
| BR112023019797A2 (pt) | Inibidor derivado heterocíclico e método de preparação do mesmo e aplicação do mesmo | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| BR112017020993A2 (pt) | compostos, processo para a síntese de compostos, composição, uso de um composto da fórmula i, método para combater fungos fitopatogênicos, e, semente. | |
| EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
| BR112018075433A2 (pt) | derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os | |
| BR112018075284A2 (pt) | derivados de piperidinila substituída por (hetero)arila, processo para sua preparação e composições farmacêuticas contendo-os | |
| BR112018007381A2 (pt) | compostos úteis como imunomoduladores | |
| BR112017019287A2 (pt) | composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| BR112018014536A2 (pt) | derivados de amônio, um processo para sua preparação e composições farmacêuticas contendo os mesmos | |
| BR112018067538A2 (pt) | inibidores de ire1-alfa de pequenas moléculas | |
| BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
| UY29360A1 (es) | Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones. | |
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| BR112017017349A2 (pt) | composto, composição, método para tratar um distúrbio | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| BR112021026498A2 (pt) | Composto, uso do composto e composição farmacêutica | |
| BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
| BR112018006519A2 (pt) | compostos de fórmula, processo para a síntese de compostos, compostos intermediários x, composição, utilização de um composto de fórmula, método para o combate de fungos e semente | |
| BR112018006314A2 (pt) | composto da fórmula, composição, uso de composto da fórmula, método de combate a fungos fitopatogênicos e semente revestida | |
| BR112018006545A2 (pt) | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? | |
| MX2021010700A (es) | Compuestos utiles en la terapia del vih. | |
| BR112022009103A2 (pt) | Compostos heterocíclicos fungicidas inovadores contendo sulfiliminas ou sulfoximinas |